Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Urology. 2020 Oct 16;148:134–140. doi: 10.1016/j.urology.2020.08.080

Figure 1.

Figure 1

Figure 1

Figure 1

Promotional payments to urologists for abiraterone or enzalutamide by HRR, sorted by rank (a). Holding the rank order constant, promotional payments to medical oncologists for abiraterone or enzalutamide (b), and all other promotional payments to all physicians (c).

Source: Authors’ analysis of Medicare Open Payments data, 2015.

Notes: Market-level payments to urologists were more strongly correlated with all other promotional payments to physicians (coefficient = 0.62) than with promotional payments to medical oncologists (coefficient = 0.42).